In April, endocrinologist Calvin Wu described how his company, Steady Health, was making use of the flowing stream of data from continuous glucose monitors to help patients with type 1 diabetes manage their blood glucose and avoid dangerous complications. That effort extended to some patients with type 2 diabetes, but he drew the line there.
“I think there may very well be a role for CGM down the road as more of a preventative kind of use case,” said Wu. “But I think the challenge here is that the evidence for that right now is fairly light.”
About the Author Reprints
Create a display name to comment
This name will appear with your comment
